Mycophenolate mofetil - Generic Drug Details

What are the generic drug sources for mycophenolate mofetil and what is the scope of freedom to operate?

Mycophenolate mofetil is the generic ingredient in four branded drugs marketed by Roche Palo, Accord Hlthcare, Alkem Labs Ltd, Apotex Corp, Aurobindo Pharma Ltd, Concord Biotech Ltd, Dr Reddys Labs Ltd, Hetero Labs Ltd V, Hikma, Jubilant Cadista, Mylan, Sandoz, Strides Pharma, Strides Pharma Intl, Teva Pharms, Wuxi, Zhejiang Hisun Pharm, Zydus Pharms Usa Inc, Amneal, Lannett Co Inc, Rising, Teva Pharms Usa, Vistapharm Llc, Azurity, Apotex, Aurobindo Pharma, Bpi Labs, Meitheal, Mylan Labs Ltd, Onesource Specialty, Ph Health, and Zydus Pharms, and is included in fifty-four NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Mycophenolate mofetil has four patent family members in three countries.

There are twenty-nine drug master file entries for mycophenolate mofetil. Thirty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for mycophenolate mofetil

International Patents:	4
US Patents:	5
Tradenames:	4
Applicants:	32
NDAs:	54
Drug Master File Entries:	29
Finished Product Suppliers / Packagers:	31
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,002
Patent Applications:	5,629
Drug Prices:	Drug price trends for mycophenolate mofetil
What excipients (inactive ingredients) are in mycophenolate mofetil?	mycophenolate mofetil excipients list
DailyMed Link:	mycophenolate mofetil at DailyMed

See drug prices for mycophenolate mofetil

Recent Clinical Trials for mycophenolate mofetil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE1
City of Hope Medical Center	PHASE1
Milton S. Hershey Medical Center	PHASE2

See all mycophenolate mofetil clinical trials

Generic filers with tentative approvals for MYCOPHENOLATE MOFETIL

Applicant	Application No.	Strength	Dosage Form
		500MG	INJECTABLE; INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for mycophenolate mofetil

Drug Class

Antimetabolite Immunosuppressant

Paragraph IV (Patent) Challenges for MYCOPHENOLATE MOFETIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CELLCEPT	For Oral Suspension	mycophenolate mofetil	200 mg/mL	050759	1	2011-03-25

US Patents and Regulatory Information for mycophenolate mofetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	CAPSULE;ORAL	090055-001	Jun 10, 2010	AB	RX	No	No
Ph Health	MYCOPHENOLATE MOFETIL HYDROCHLORIDE	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	203575-001	Oct 28, 2016	AP	RX	No	No
Teva Pharms	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	CAPSULE;ORAL	065491-001	May 6, 2009	AB	RX	No	No
Rising	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	FOR SUSPENSION;ORAL	213955-001	Sep 11, 2023	AB	RX	No	No
Mylan	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	CAPSULE;ORAL	065520-001	May 4, 2009	AB	RX	No	No
Roche Palo	CELLCEPT	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	050758-001	Aug 12, 1998	AP	RX	Yes	Yes

Expired US Patents for mycophenolate mofetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	CELLCEPT	mycophenolate mofetil	CAPSULE;ORAL	050722-001	May 3, 1995	4,753,935
Roche Palo	CELLCEPT	mycophenolate mofetil	TABLET;ORAL	050723-001	Jun 19, 1997	4,753,935
Roche Palo	CELLCEPT	mycophenolate mofetil	FOR SUSPENSION;ORAL	050759-001	Oct 1, 1998	5,688,529
Roche Palo	CELLCEPT	mycophenolate mofetil	FOR SUSPENSION;ORAL	050759-001	Oct 1, 1998	4,753,935

EU/EMA Drug Approvals for mycophenolate mofetil

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Passauer Pharma GmbH	Myclausen	mycophenolate mofetil	EMEA/H/C/001218Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.,	Authorised	yes	no	no	2010-10-07
Roche Registration GmbH	CellCept	mycophenolate mofetil	EMEA/H/C/000082CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.	Authorised	no	no	no	1996-02-14
Teva B.V.	Myfenax	mycophenolate mofetil	EMEA/H/C/000884Myfenax is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.	Authorised	yes	no	no	2008-02-21
Teva Pharma B.V.	Mycophenolate mofetil Teva	mycophenolate mofetil	EMEA/H/C/000882Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.	Authorised	yes	no	no	2008-02-21

International Patents for mycophenolate mofetil

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3836898	SUSPENSION PHARMACEUTIQUE POUR FORME GALÉNIQUE ORALE (PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE)
United Kingdom	2591396	Pharmaceutical suspension for oral dosage
World Intellectual Property Organization (WIPO)	2020039263
United Kingdom	202103764

Supplementary Protection Certificates for mycophenolate mofetil

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0281713	SPC/GB96/026	United Kingdom		PRODUCT NAME: MYCOPHENOLATE MOFETIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 53337 19951103; CH 53338 19951103; UK EU/1/96/005/001 19960214; UK EU/96/005/002 19960214
0281713	96C0031	Belgium		PRODUCT NAME: MYCOPHENOLATE MOFETIL; NAT. REGISTRATION NO/DATE: EU/1/96/005/001 19960214; FIRST REGISTRATION: CH 53337 19951103

Market Dynamics and Financial Trajectory for Mycophenolate Mofetil

Last updated: July 28, 2025

Introduction

Mycophenolate mofetil (MMF), marketed primarily under the brand name CellCept, is an immunosuppressant drug extensively used globally for preventing organ transplant rejection and treating certain autoimmune diseases. Its market landscape is shaped by evolving clinical practices, regulatory approvals, competitive pressures, and patent statuses. Understanding these dynamics is central for stakeholders—pharmaceutical companies, investors, healthcare providers, and policymakers—aiming to navigate the complex trajectory of MMF's commercial and therapeutic value.

---

Pharmacological Profile and Therapeutic Context

MMF functions as a prodrug of mycophenolic acid, selectively inhibiting inosine monophosphate dehydrogenase, which impairs lymphocyte proliferation. Its efficacy in preventing allograft rejection after kidney, heart, and lung transplants underscores its prominent role within the immunosuppressive therapy landscape. Moreover, recent off-label applications, such as managing certain autoimmune diseases, are expanding its utility, albeit under regulatory and clinical debate.

---

Market Size and Key Drivers

Global Market Valuation and Growth Trends

The global mycophenolate mofetil market was valued at approximately USD 2.5 billion in 2022, with projections indicating a compound annual growth rate (CAGR) of 5-7% through 2030. Growth is driven primarily by increasing rates of organ transplantation, expanding indications, and rising incidence of autoimmune conditions needing immunosuppression. Notably, North America and Europe dominate market share owing to high transplant volumes, advanced healthcare infrastructure, and favorable reimbursement policies.

Clinical and Demographic Drivers

• Organ Transplantation Volumes: Rising transplant procedures, particularly in emerging economies, directly stimulate MMF demand. According to the Global Observatory on Donation and Transplantation, transplant numbers increased by approximately 4% annually over the past five years.
• Autoimmune Diseases Prevalence: The growing burden of diseases such as systemic lupus erythematosus (SLE) and other autoimmune disorders enhances MMF's off-label utilization.
• Regulatory Approvals: Expanding indications and approvals for pediatric or specific transplant types foster market growth.

---

Market Dynamics Influencing Growth

Patent and Manufacturing Patents:

Despite the expiry of the original patent in major markets around 2018-2020, generic versions of MMF increased market penetration, intensifying price competition. Patent cliff effects initially suppressed revenues for innovator companies but introduced affordable generics that spurred wider drug accessibility.

Generic Competition and Pricing Dynamics

The proliferation of generics post-patent expiry has led to significant price erosion, reducing brand-name drug revenues. However, generic manufacturers face challenges tied to bioequivalence standards and manufacturing quality controls, particularly across low-to-middle-income countries.

Regulatory Environment and Approvals

Regulatory agencies such as the FDA and EMA have provided guidance for manufacturing standards and expanded indications, fostering new applications. Conversely, the withdrawal of some approvals or restrictions on off-label uses can curtail market expansion.

Emerging Alternatives and Competition

New immunosuppressant agents like belatacept, bortezomib, and other targeted therapies challenge MMF's market dominance in transplantation, prompting a shift towards combination therapies or alternative first-line agents.

Supply Chain and Manufacturing Factors

Global supply chain disruptions, particularly during the COVID-19 pandemic, impacted steady drug availability. Consolidation among manufacturing firms has both improved quality control and constrained supply, influencing market prices.

---

Financial Trajectory and Investment Outlook

Revenue Trends and Forecasts

Revenue growth experienced a moderate decline post-patent expiry but is expected to stabilize owing to increasing transplant volumes and off-label uses. The introduction of biosimilars in specific markets may further pressure pricing but can ultimately expand market size by reducing costs.

Research and Development Investment

Major pharmaceutical players continue investing in novel formulations, combination therapies, and new indications, fueling incremental growth. For instance, development of extended-release formulations or targeted immunosuppressants could reshape the revenue dynamics.

Market Risks and Challenges

• Regulatory Risks: Changes in approval status for certain indications.
• Pricing Pressure: Accelerated generic entry and health policy shifts favoring cost-effective options.
• Clinical Risks: Emergence of adverse effects or safety concerns impacting prescribing patterns.
• Patent Litigation and Exclusivity: Ongoing patent litigation or delays in exclusivity periods influence market control and profitability.

---

Future Outlook and Market Opportunities

The outlook for MMF hinges on the broader transplantation and autoimmune therapy landscapes. While generic competition presents challenges, opportunities lie in:

• Expanding indications for pediatric and specific transplant populations.
• Developing novel formulations enhancing patient adherence.
• Strategic partnerships and licensing deals to extend patent life and market penetration.
• Utilizing biosimilars to offer more affordable options, increasing global access.

Emerging markets, with their expanding healthcare infrastructure, represent significant growth opportunities, albeit with market-specific regulatory hurdles.

---

Key Takeaways

• The mycophenolate mofetil market is mature but resilient, driven by transplant volume increases and autoimmune disease management.
• Patent expiry catalyzed generic competition, exerting downward pressure on prices but expanding global access.
• Innovative formulations and expanded indications may create new revenue streams, despite competitive and regulatory headwinds.
• Market consolidation and strategic alliances are pivotal for sustaining profitability amid biosimilar entry and evolving healthcare policies.
• Emerging markets offer substantial growth prospects, provided regulatory and manufacturing barriers are managed effectively.

---

Frequently Asked Questions

1. What are the primary factors affecting MMF's market growth?
   The growth is mainly driven by increased transplantation procedures, expanding indications, regulatory approvals, and demographic shifts. Conversely, patent expiries and generic competition exert downward price pressures.

2. How does patent expiration impact the commercial landscape of MMF?
   Patent expiry leads to the emergence of generics, reducing revenues for brand-name formulations but increasing market accessibility and volume, especially in price-sensitive regions.

3. What are the key challenges faced by MMF market players?
   Challenges include intense generic competition, regulatory restrictions on off-label uses, safety concerns, supply chain disruptions, and pricing pressures.

4. Are there significant emerging markets for MMF?
   Yes, emerging economies are experiencing rapid growth in transplantation activities and healthcare infrastructure, offering substantial opportunities for market expansion.

5. What are future innovation prospects for mycophenolate mofetil?
   Innovations include novel formulations for improved patient compliance, combination therapies, and expanded indications for autoimmune diseases or pediatric use.

---

References

[1] MarketResearch.com, "Global Mycophenolate Mofetil Market Size, Share & Industry Analysis," 2022.
[2] Global Observatory on Donation and Transplantation (GODT), "Transplant Trends," 2021.
[3] U.S. Food and Drug Administration (FDA), "Approved Drugs Database," 2022.
[4] IMS Health, "Pharmaceutical Market Report," 2022.
[5] World Health Organization, "Transplant Data and Statistics," 2021.